In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
在2型糖尿病中，SGLT-2 抑制劑對心血管和腎臟結果的影響與GLP-1 受體激動劑的使用無關。
Ann Intern Med 2024-11-04
Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.
減重介入對多囊卵巢症候群症狀負擔及生物標記的影響：隨機對照試驗的系統性回顧。
Ann Intern Med 2024-11-04
In adults with BMI ≥27 kg/m<sup>2</sup> and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA<sub>1c</sub> level.
在體重指數 (BMI) ≥27 kg/m<sup>2</sup> 且有心血管疾病 (CVD) 的成人中，無糖尿病的情況下，semaglutide 減少了主要不良心血管事件 (MACE)，無論基線 HbA<sub>1c</sub> 水平如何。
Ann Intern Med 2024-11-04
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Survodutide 治療肥胖的理由及兩項隨機第三期臨床試驗（SYNCHRONIZE™-1 和 -2）的設計。
Obesity (Silver Spring) 2024-11-04
Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy.
雙重轉基因新生豬胰島作為β細胞替代療法的替代來源。
Proc Natl Acad Sci U S A 2024-11-04
Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.
GLP-1 受體激動劑對前列腺癌風險降低的影響：系統性回顧與統合分析。
Int Urol Nephrol 2024-11-04
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications.
Oxyntomodulin 生理學及其在肥胖及相關併發症中的治療發展。
J Physiol 2024-11-04